Insulin Family advanced
Soliqua/Suliqua Co-Formulation Technology
Dual-chamber pen device technology enabling stable co-formulation of insulin glargine and lixisenatide.
By Encyclopeptide Editorial | 1 min read
insulin glargine lixisenatide co-formulation pen-device
Overview
Soliqua/Suliqua represents a challenging co-formulation requiring compatibility between two chemically distinct peptides in a single delivery device.
Formulation Challenges
- pH compatibility: Glargine requires pH 4.0; lixisenatide requires pH 5-7
- Stability: Both peptides must remain stable in combined formulation
- Aggregation prevention: Minimizing peptide aggregation over 28-day use
- Dosing accuracy: Maintaining correct ratio throughout use
Dual-Chamber Design
- Chamber 1: Insulin glargine (100 U/mL)
- Chamber 2: Lixisenatide (33 mcg/mL)
- Mixing occurs during injection
- Fixed ratio maintained throughout use
Chemical Identity
| Property | Value |
|---|---|
| Name | Soliqua/Suliqua Co-Formulation Technology |
| Category | Insulin Family |
References
- Encyclopeptide Database. “Soliqua/Suliqua Co-Formulation Technology” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Soliqua/Suliqua Co-Formulation Technology with interactive quizzes on Wikipept.
Take a Quiz on Wikipept